Asymmetric Synthesis and Absolute Configuration of (+)- and (–)-Perhexiline

Research output: Contribution to journalArticle

4 Citations (Scopus)
4 Downloads (Pure)

Abstract

Racemic perhexiline has been used (or is currently undergoing clinical trials) for the treatment of a variety of cardiovascular disorders. Increasing evidence suggests that the (–)-enantiomer should be used, as opposed to the racemic mixture. Here, we report the first asymmetric synthesis of both enantiomers of perhexiline in high enantiomeric excess and the assignment of their (–)-S/(+)-R absolute stereochemistry by X-ray crystallography.
Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalSynthesis
Volume48
Issue number01
Early online date27 Oct 2015
DOIs
Publication statusPublished - Jan 2016

Fingerprint

Perhexiline
Enantiomers
Stereochemistry
X ray crystallography

Keywords

  • perhexiline
  • asymmetric analysis
  • stereochemistry
  • medicinal chemistry
  • crystal structure

Cite this

Asymmetric Synthesis and Absolute Configuration of (+)- and (–)-Perhexiline. / Tseng, Chih-Chung; Greig, Iain R.; Harrison, William T. A.; Zanda, Matteo.

In: Synthesis, Vol. 48, No. 01, 01.2016, p. 73-78.

Research output: Contribution to journalArticle

@article{c556fff83ca14db88cb15e5f8c3c97c8,
title = "Asymmetric Synthesis and Absolute Configuration of (+)- and (–)-Perhexiline",
abstract = "Racemic perhexiline has been used (or is currently undergoing clinical trials) for the treatment of a variety of cardiovascular disorders. Increasing evidence suggests that the (–)-enantiomer should be used, as opposed to the racemic mixture. Here, we report the first asymmetric synthesis of both enantiomers of perhexiline in high enantiomeric excess and the assignment of their (–)-S/(+)-R absolute stereochemistry by X-ray crystallography.",
keywords = "perhexiline, asymmetric analysis, stereochemistry, medicinal chemistry, crystal structure",
author = "Chih-Chung Tseng and Greig, {Iain R.} and Harrison, {William T. A.} and Matteo Zanda",
note = "We gratefully thank Signal Pharma for financial support and fellowship (C.C.T), and the EPSRC National Mass Spectrometry Service Centre (Swansea, UK) for performing HRMS analyses. We thank Prof Michael Frenneaux (University of East Anglia, Norwich, UK) for useful and stimulating discussions.",
year = "2016",
month = "1",
doi = "10.1055/s-0035-1560708",
language = "English",
volume = "48",
pages = "73--78",
journal = "Synthesis",
issn = "0039-7881",
publisher = "GEORG THIEME VERLAG KG",
number = "01",

}

TY - JOUR

T1 - Asymmetric Synthesis and Absolute Configuration of (+)- and (–)-Perhexiline

AU - Tseng, Chih-Chung

AU - Greig, Iain R.

AU - Harrison, William T. A.

AU - Zanda, Matteo

N1 - We gratefully thank Signal Pharma for financial support and fellowship (C.C.T), and the EPSRC National Mass Spectrometry Service Centre (Swansea, UK) for performing HRMS analyses. We thank Prof Michael Frenneaux (University of East Anglia, Norwich, UK) for useful and stimulating discussions.

PY - 2016/1

Y1 - 2016/1

N2 - Racemic perhexiline has been used (or is currently undergoing clinical trials) for the treatment of a variety of cardiovascular disorders. Increasing evidence suggests that the (–)-enantiomer should be used, as opposed to the racemic mixture. Here, we report the first asymmetric synthesis of both enantiomers of perhexiline in high enantiomeric excess and the assignment of their (–)-S/(+)-R absolute stereochemistry by X-ray crystallography.

AB - Racemic perhexiline has been used (or is currently undergoing clinical trials) for the treatment of a variety of cardiovascular disorders. Increasing evidence suggests that the (–)-enantiomer should be used, as opposed to the racemic mixture. Here, we report the first asymmetric synthesis of both enantiomers of perhexiline in high enantiomeric excess and the assignment of their (–)-S/(+)-R absolute stereochemistry by X-ray crystallography.

KW - perhexiline

KW - asymmetric analysis

KW - stereochemistry

KW - medicinal chemistry

KW - crystal structure

U2 - 10.1055/s-0035-1560708

DO - 10.1055/s-0035-1560708

M3 - Article

VL - 48

SP - 73

EP - 78

JO - Synthesis

JF - Synthesis

SN - 0039-7881

IS - 01

ER -